International Biotechnology Trust plc

International Biotechnology Trust plc focuses its capital allocation primarily on companies in their development and late-stage phases. A substantial portion of its assets is dedicated to publicly traded small and mid-capitalization enterprises, with a smaller allocation to larger listed firms. Pursuing a long-only investment approach, the Trust targets both quoted and unquoted biotechnology and life sciences companies, particularly those involved in drug discovery and development. Related sectors of interest encompass microbiology, broader life sciences, pharmaceutical research and development, gene research and development, medical devices, and healthcare services. The fund actively seeks out companies engaged in the creation, advancement, and commercialization of novel products, medical devices, or foundational technologies, including those within the therapeutic sub-sector. A key criterion for investment is a strong growth outlook, often driven by the successful development or market introduction of a biotechnology drug candidate, medical device, or other innovative medical research tool. Investments may also extend to specialty pharmaceuticals and life science instrumentation. The spectrum of investee companies ranges from early-stage private firms with robust scientific foundations requiring development capital, to established, multi-billion dollar biotechnology and medical device corporations with extensive product portfolios already widely adopted in global healthcare settings. While the majority of its capital is deployed in smaller and mid-cap publicly traded entities, the Trust aims to commit up to 30% of its assets to privately held ventures. It allows for an aggregate exposure to unquoted companies of up to 40% at the time of initial investment, accounting for any valuation increases and subsequent funding. Although the United States represents a typical geographical focus, the Trust actively seeks optimal investment opportunities worldwide, including in Western Europe, Australia, and Asia. Individual investments in portfolio companies generally range from $1 million to $4 million. Exits for its unquoted holdings are typically realized either through their sale to strategic acquirers, such as major pharmaceutical corporations, or, in certain instances, via public flotation (IPO).